Filter by

  • Publication Year
  • Availability
  • Attachment
  • Collection Type
    See More
  • General Material Designation
    See More
  • Location
    See More
  • Language
Found 4 from your keywords: subject="Atrial Fibrillation"
cover
Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients…
Comment Share
Chan YH

Edoxaban, apixaban, and rivaroxaban were associated with a lower risk of ischemic stroke/systemic embolism than warfarin. All DOACs had a lower risk of major bleeding than warfarin. Apixaban was associated with a lower risk of major bleeding than rivaroxaban and dabigatran, whereas the risk ofmajor bleeding was comparable between edoxaban and apixaban. The reduced risks of thromboembolism/majo…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a…
Comment Share
Guimarães PO

In these meta-analyses, a lower rate of death was seen both with warfarin (odds ratio [OR] 0.74, 95% confidence interval [CI] 0.57–0.97) and aspirin (OR 0.86, 95% CI 0.69–1.07) versus placebo/no treatment. Using data from ARISTOTLE and AVERROES, apixaban reduced the risk of death by 34% (95% CI 12–50%; p = 0.004) and 33% (95% CI 6–52%; p = 0.02), respectively, when compared with an i…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Apixaban to prevent stroke in patients with atrial fibrillation: a review
Comment Share
Peterson BE

Atrial fibrillation is a common, costly and morbid cardiovascular arrhythmia. Stroke prevention remains the mainstay of treatment for atrial fibrillation, and the recent advent of novel oral anticoagulants with direct factor IIa or factor Xa inhibition has significantly revolutionized this aspect of treatment for atrial fibrillation patients. This review focuses on the tolerability and efficac…

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-
cover
Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular…
Comment Share
Dawwas GK

Although apixaban and rivaroxaban are commonly used in patients with atrial fibrillation (AF) and valvular heart disease (VHD), there is limited evidence comparing the 2 drugs in these patients

Edition
-
ISBN/ISSN
-
Collation
-
Series Title
-
Call Number
-